文献速递类风湿关节炎

高剂量与低剂量泼尼松龙短期桥接策略对活动性早期类风湿关节炎放射学与临床结局的疗效:双盲随机安慰剂对照试验

The Efficacy of Short-Term Bridging Strategies With High- and Low-Dose Prednisolone on Radiographic and Clinical Outcomes in Active Early Rheumatoid Arthritis: A Double-Blind, Randomized, Placebo-Controlled Trial.
PubMed 文献 · Arthritis Rheumatol · 2022-01-01

该双盲随机安慰剂对照试验纳入395例中高疾病活动度的早期类风湿关节炎成人患者,比较60mg泼尼松龙、10mg泼尼松龙(均在12周内减至0mg)与安慰剂三种桥接策略。1年后三组改良Sharp/van der Heijde评分变化相当,高剂量泼尼松龙相比安慰剂无优效性;12周时DAS28-ESR有差异,但52周时三组无显著差异。

要点

  • 1年后SHS评分变化:高剂量组1.0±2.0、低剂量组1.1±2.2、安慰剂组1.1±1.5,高剂量相比安慰剂估计差值-0.04(95%CI -0.5, 0.4),无优效性。
  • 12周时DAS28-ESR变化:高剂量组相比安慰剂-0.6(95%CI -1.0, -0.2),低剂量组相比安慰剂-0.8(95%CI -1.2, -0.5)。
  • 52周时三组DAS28-ESR无显著差异(范围2.6-2.8),严重不良事件发生情况相似。

核心结论

  • 高剂量短期糖皮质激素桥接治疗在1年放射学损伤进展方面未显示获益。

研究设计与样本

  • 双盲、随机、安慰剂对照试验,来自1家风湿病医院和23家风湿病诊所的成人活动性早期类风湿关节炎患者。
  • 按1:1:1随机分配至60mg泼尼松龙(高剂量组)、10mg泼尼松龙(低剂量组)每日口服(12周内减至0mg)或安慰剂。
  • 12周干预期后为40周由医生酌情决定的治疗期。
  • 共随机395例(高剂量组n=132,低剂量组n=131,安慰剂组n=132),375例(95%)纳入改良意向治疗分析。

主要发现

  • 1年后SHS评分平均变化:高剂量组1.0±2.0单位,低剂量组1.1±2.2单位,安慰剂组1.1±1.5单位。
  • 主要分析显示高剂量组相比安慰剂无优效性,估计差值-0.04(95%CI -0.5, 0.4)。
  • 12周时DAS28-ESR平均差异:高剂量组相比安慰剂-0.6(95%CI -1.0, -0.2),低剂量组相比安慰剂-0.8(95%CI -1.2, -0.5)。
  • 52周时三组DAS28-ESR无显著差异(范围2.6-2.8)。
  • 严重不良事件发生情况相似。

关键数值与推荐

  • 主要结局为1年时采用改良Sharp/van der Heijde总分(SHS)测量的放射学变化。
  • 疾病活动度采用基于红细胞沉降率的28关节疾病活动度评分(DAS28-ESR)评估。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: In active early rheumatoid arthritis (RA), glucocorticoids are often used for bridging, due to the delayed action of methotrexate. This study was undertaken to compare the effect of 3 bridging strategies, including high-dose and low-dose prednisolone, on radiographic and clinical outcomes. METHODS: Adult RA patients from 1 rheumatology hospital and 23 rheumatology practices who presented with moderate/high disease activity were randomized (1:1:1) to receive 60 mg prednisolone (high-dose prednisolone [HDP]) or 10 mg prednisolone (low-dose prednisolone [LDP]) daily (tapered to 0 mg within 12 weeks) or placebo. The 12-week intervention period was followed by 40 weeks of therapy at the physicians' discretion. The primary outcome measure was radiographic change at 1 year measured using the total modified Sharp/van der Heijde score (SHS). Disease activity was assessed with the Disease Activity Score in 28 joints using the erythrocyte sedimentation rate (DAS28-ESR). RESULTS: Of 395 randomized patients (HDP, n = 132; LDP, n = 131; placebo, n = 132), 375 (95%) remained in the modified intention-to-treat analysis. Mean ± SD changes in SHS scores in the 3 groups after 1 year were comparable: mean ± SD 1.0 ± 2.0 units in the HDP group, 1.1 ± 2.2 units in the LDP group, and 1.1 ± 1.5 units in the placebo group. The primary analysis showed no superiority of HDP compared to placebo (estimated difference of the mean change -0.04 [95% confidence interval (95% CI) -0.5, 0.4]). At week 12, the mean DAS28-ESR differed: -0.6 (95% CI -1.0, -0.2) for HDP versus placebo; -0.8 (95% CI -1.2, -0.5) for LDP versus placebo. At week 52, there was no significant difference in DAS28-ESR between the 3 groups (range 2.6-2.8). Serious adverse events occurred similarly often. CONCLUSION: Short-term glucocorticoid bridging therapy at a high dose showed no benefit with regard to progression of radiographic damage at 1 year.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Krause D, Mai A, Klaassen-Mielke R, et al. The Efficacy of Short-Term Bridging Strategies With High- and Low-Dose Prednisolone on Radiographic and Clinical Outcomes in Active Early Rheumatoid Arthritis: A Double-Blind, Randomized, Placebo-Controlled Trial. Arthritis Rheumatol. 2022. PMID: 35643951. doi:10.1002/art.42245

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。